Get Started

NOVN

Novan (NOVN)

Novan Inc

Date:

Regulatory News

Text Search:

Sort by:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:NOVN

1 2 3 4 5 6 7 8 9 10 Next >>

Date	Time	Source	Headline	Symbol	Company
05/16/2024	12:13PM	iHub Newswire	FeaturedCannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology
05/02/2024	12:15AM	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:NOVN	Novan Inc
05/02/2024	12:15AM	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:NOVN	Novan Inc
05/02/2024	12:15AM	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:NOVN	Novan Inc
05/01/2024	11:49AM	Edgar (US Regulatory)	Form POS AM - Post-Effective amendments for registration statement	NASDAQ:NOVN	Novan Inc
05/01/2024	11:48AM	Edgar (US Regulatory)	Form POS AM - Post-Effective amendments for registration statement	NASDAQ:NOVN	Novan Inc
05/01/2024	11:44AM	Edgar (US Regulatory)	Form POS AM - Post-Effective amendments for registration statement	NASDAQ:NOVN	Novan Inc
05/01/2024	11:41AM	Edgar (US Regulatory)	Form POS AM - Post-Effective amendments for registration statement	NASDAQ:NOVN	Novan Inc
05/01/2024	11:37AM	Edgar (US Regulatory)	Form POS AM - Post-Effective amendments for registration statement	NASDAQ:NOVN	Novan Inc
03/25/2024	8:54AM	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NOVN	Novan Inc
02/26/2024	4:22PM	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NOVN	Novan Inc
01/30/2024	4:47PM	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NOVN	Novan Inc
01/26/2024	4:38PM	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NOVN	Novan Inc
01/05/2024	9:23AM	GlobeNewswire Inc.	Novartis expands production of Pluvicto™ with addition of its largest and most advanced radioligand therapy manufacturing facility in Indianapolis	NASDAQ:NOVN	Novan Inc
12/21/2023	4:13PM	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NOVN	Novan Inc
12/10/2023	7:30PM	GlobeNewswire Inc.	Novartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and long-term safety of Fabhalta® (iptacopan) in adults with paroxysmal nocturnal hemoglobinuria (PNH)	NASDAQ:NOVN	Novan Inc
12/08/2023	9:15AM	GlobeNewswire Inc.	Latest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broad population of patients with early breast cancer; supports regulatory submissions	NASDAQ:NOVN	Novan Inc
12/05/2023	7:16PM	GlobeNewswire Inc.	Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH	NASDAQ:NOVN	Novan Inc
11/20/2023	1:15AM	GlobeNewswire Inc.	Novartis showcases significant data updates from Kisqali®, iptacopan and Scemblix® at SABCS and ASH	NASDAQ:NOVN	Novan Inc
10/24/2023	5:01PM	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NOVN	Novan Inc
10/20/2023	5:00PM	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NOVN	Novan Inc
09/07/2023	4:58PM	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NOVN	Novan Inc
08/24/2023	4:31PM	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NOVN	Novan Inc
07/26/2023	4:50PM	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NOVN	Novan Inc
07/17/2023	4:30PM	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NOVN	Novan Inc
07/17/2023	9:23AM	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NOVN	Novan Inc
07/17/2023	8:45AM	GlobeNewswire Inc.	Novan Enters into Agreement to Sell Substantially All of its Assets, including Berdazimer Gel, 10.3% (SB206), and Files for Chapter 11 Protection	NASDAQ:NOVN	Novan Inc
07/06/2023	5:00PM	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NOVN	Novan Inc
06/27/2023	6:30PM	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:NOVN	Novan Inc
06/16/2023	5:02PM	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:NOVN	Novan Inc